Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.46 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.46 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.45 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.45 |
| ▸ | CBLB | Q13191 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2299632 | 0.93 | KCNK3 (0.51) | KCNK3LMNARAB9AKCNQ3KCNQ2 | |
| SCHEMBL2295869 | 0.92 | NPC1 (0.50) | LMNARAB9ANPC1MAPTMEN1 | |
| SCHEMBL2295674 | 0.89 | NPC1 (0.56) | LMNARAB9ANPC1MAPTMEN1 | |
| SCHEMBL2291378 | 0.86 | NPC1 (0.62) | KCNK3LMNARAB9ANPC1MAPT | |
| SCHEMBL2298695 | 0.86 | RAB9A (0.48) | LMNARAB9ANPC1MAPTMEN1 | |
| SCHEMBL2292708 | 0.86 | NPC1 (0.48) | LMNARAB9ANPC1MAPTPTGS1 | |
| SCHEMBL2298685 | 0.86 | NPC1 (0.48) | LMNARAB9ANPC1MAPTMEN1 | |
| SCHEMBL5294216 | 0.86 | AVPR2 (0.46) | KCNK3LMNARAB9ANPC1ALDH1A1 | |
| SCHEMBL2300670 | 0.85 | NPC1 (0.49) | LMNARAB9ANPC1MAPTMEN1 | |
| SCHEMBL5301051 | 0.85 | AURKA (0.47) | LMNARAB9ANPC1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003806-B2 | Integrin antagonists useful as anticancer agents | OSI Pharmaceuticals, LLC (US) | 2011-08-23 | — | — | US | claimed |
| EP-1828144-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ALCATEL LUCENT (FR) | 2006-06-01 | — | — | US | claimed |
| WO-2006053342-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ITGB5, ITGA5, ITGB1 | KCNK3 1691/4885LMNA 1740/4885RAB9A 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.